283 related articles for article (PubMed ID: 31851436)
21. Efficacy of combined use of Suvorexant and Ramelteon in preventing postoperative delirium: a retrospective comparative study.
Ikeuchi S; Tanaka R; Sugiura T; Shinsato K; Wakabayashi A; Sato J; Suzuki K; Shino M
J Pharm Health Care Sci; 2023 Dec; 9(1):42. PubMed ID: 38037168
[TBL] [Abstract][Full Text] [Related]
22. Prompt improvement of difficulty with sleep initiation and waking up in the morning and daytime somnolence by combination therapy of suvorexant and ramelteon in delayed sleep-wake phase disorder: a case series of three patients.
Izuhara M; Kawano K; Otsuki K; Hashioka S; Inagaki M
Sleep Med; 2021 Apr; 80():100-104. PubMed ID: 33588260
[TBL] [Abstract][Full Text] [Related]
23. Ramelteon for Prevention of Postoperative Delirium: A Randomized Controlled Trial in Patients Undergoing Elective Pulmonary Thromboendarterectomy.
Jaiswal SJ; Vyas AD; Heisel AJ; Ackula H; Aggarwal A; Kim NH; Kerr KM; Madani M; Pretorius V; Auger WR; Fernandes TM; Malhotra A; Owens RL
Crit Care Med; 2019 Dec; 47(12):1751-1758. PubMed ID: 31567351
[TBL] [Abstract][Full Text] [Related]
24. Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts.
Svetnik V; Snyder ES; Tao P; Scammell TE; Roth T; Lines C; Herring WJ
Sleep; 2018 Jan; 41(1):. PubMed ID: 29112763
[TBL] [Abstract][Full Text] [Related]
25. Non-24-hour sleep-wake disorder successfully treated with the combination of ramelteon and suvorexant in a case of autism spectrum disorder.
Iwata M; Kaneko K
Neuropsychopharmacol Rep; 2020 Dec; 40(4):383-387. PubMed ID: 32990413
[TBL] [Abstract][Full Text] [Related]
26. Ramelteon and suvorexant for postoperative delirium in elderly patients with esophageal cancer.
Mayanagi S; Haneda R; Inoue M; Ishii K; Tsubosa Y
Esophagus; 2023 Oct; 20(4):635-642. PubMed ID: 37561254
[TBL] [Abstract][Full Text] [Related]
27. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease.
Sun H; Palcza J; Rosenberg R; Kryger M; Siringhaus T; Rowe J; Lines C; Wagner JA; Troyer MD
Respir Med; 2015 Mar; 109(3):416-26. PubMed ID: 25661282
[TBL] [Abstract][Full Text] [Related]
28. Safety profile and clinical course of patients with insomnia administered suvorexant by initial treatment status in a post-marketing survey.
Sano H; Asai Y; Miyazaki M; Iwakura M; Maeda Y; Hara M
Expert Opin Drug Saf; 2019 Nov; 18(11):1109-1118. PubMed ID: 31478753
[No Abstract] [Full Text] [Related]
29. Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis.
Kuriyama A; Tabata H
Sleep Med Rev; 2017 Oct; 35():1-7. PubMed ID: 28365447
[TBL] [Abstract][Full Text] [Related]
30. Chronotherapeutic efficacy of suvorexant on sleep quality and metabolic parameters in patients with type 2 diabetes and insomnia.
Yoshikawa F; Shigiyama F; Ando Y; Miyagi M; Uchino H; Hirose T; Kumashiro N
Diabetes Res Clin Pract; 2020 Nov; 169():108412. PubMed ID: 32911037
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Transitioning to Lemborexant from Z-drug, Suvorexant, and Ramelteon in Japanese Insomnia Patients: An Open-label, Multicenter Study.
Ozone M; Hirota S; Ariyoshi Y; Hayashida K; Ikegami A; Habukawa M; Ohshima H; Harada D; Hiejima H; Kotorii N; Murotani K; Taninaga T; Uchimura N
Adv Ther; 2024 Apr; 41(4):1728-1745. PubMed ID: 38460107
[TBL] [Abstract][Full Text] [Related]
32. Ramelteon for the treatment of delirium in elderly patients: a consecutive case series study.
Tsuda A; Nishimura K; Naganawa E; Otsubo T; Ishigooka J
Int J Psychiatry Med; 2014; 47(2):97-104. PubMed ID: 25084796
[TBL] [Abstract][Full Text] [Related]
33. Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data.
Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
Psychopharmacology (Berl); 2017 Jun; 234(11):1703-1711. PubMed ID: 28265715
[TBL] [Abstract][Full Text] [Related]
34. Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
Kishi T; Matsunaga S; Iwata N
PLoS One; 2015; 10(8):e0136910. PubMed ID: 26317363
[TBL] [Abstract][Full Text] [Related]
35. Residual effects of low dose of suvorexant, zolpidem, and ramelteon in healthy elderly subjects: A randomized double-blind study.
Uemura SI; Imanishi A; Terui Y; Park I; Satake M; Han G; Shioya T; Kanbayashi T; Nishino S
Neuropsychopharmacol Rep; 2022 Sep; 42(3):288-298. PubMed ID: 35748642
[TBL] [Abstract][Full Text] [Related]
36. A Review of Suvorexant, Doxepin, Ramelteon, and Tasimelteon for the Treatment of Insomnia in Geriatric Patients.
Edmonds C; Swanoski M
Consult Pharm; 2017 Mar; 32(3):156-160. PubMed ID: 28270270
[TBL] [Abstract][Full Text] [Related]
37. Use of Suvorexant and Antipsychotics in the Treatment of Delirium After Infectious Diseases: A Retrospective Study.
Okino K; Yamada H; Tomioka H; Nozaki S; Iwanami A; Inamoto A
J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):589-593. PubMed ID: 34411006
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of Ramelteon for delirium after lung cancer surgery.
Miyata R; Omasa M; Fujimoto R; Ishikawa H; Aoki M
Interact Cardiovasc Thorac Surg; 2017 Jan; 24(1):8-12. PubMed ID: 27624354
[TBL] [Abstract][Full Text] [Related]
39. Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials.
Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
Am J Geriatr Psychiatry; 2017 Jul; 25(7):791-802. PubMed ID: 28427826
[TBL] [Abstract][Full Text] [Related]
40. Suvorexant for Adults with Insomnia.
Scarff JR
J S C Med Assoc; 2015; 111(1):28-9. PubMed ID: 27124984
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
